Article
Medicine, Research & Experimental
Somayeh Hashemi Sheikhshabani, Zeinab Amini-Farsani, Shima Rahmati, Ali Jazaeri, Marzieh Mohammadi-Samani, Samira Asgharzade
Summary: The study revealed that oleuropein regulated the expression of miRNAs in ovarian cancer cells, potentially resulting in apoptosis induction, cell proliferation inhibition, and decline in cisplatin resistance. Further experiments in animal models of ovarian cancer are suggested to confirm the findings.
Article
Biochemistry & Molecular Biology
Kosuke Yoshida, Akira Yokoi, Mai Sugiyama, Shingo Oda, Kazuhisa Kitami, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Kaoru Niimi, Shiro Suzuki, Fumitaka Kikkawa, Tsuyoshi Yokoi, Hiroaki Kajiyama
Summary: This study identified a specific downregulation of miRNA expression levels in recurrent/metastatic OCCC, suggesting their involvement in chemoresistance. The chrXq27.3 miRNA cluster and its target genes may serve as potential therapeutic targets for overcoming resistance in OCCC.
Article
Cell Biology
Cristina Corno, Padraig D'Arcy, Marina Bagnoli, Biagio Paolini, Matteo Costantino, Nives Carenini, Elisabetta Corna, Paola Alberti, Delia Mezzanzanica, Diego Colombo, Stig Linder, Noemi Arrighetti, Paola Perego
Summary: This study identified the increased activity of ubiquitin protease USP8 in cisplatin-resistant cells and demonstrated that silencing of USP8 decreased cancer cell survival and increased sensitivity to cisplatin. Immunohistochemical analysis of clinical specimens indicated that USP8 positivity is associated with adverse prognosis in advanced stage ovarian carcinoma. Therefore, USP8 may serve as a diagnostic marker and therapeutic target to improve the efficacy of platinum-based therapy in ovarian carcinoma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yi Cai, Baiping An, Dejiao Yao, Hong Zhou, Jie Zhu
Summary: MiR-30a mediates cisplatin resistance in ovarian cancer by inhibiting autophagy via the TGF-beta/Smad4 pathway. Overexpression of miR-30a reduces the expression of Smad4 and TGF-beta, inhibits DDP-induced autophagy, and promotes apoptosis in DDP-resistant cells.
Article
Oncology
Ching-Hu Wu, Chien-Wei Feng, Chiu-Lin Wang, Zhi-Hong Wen, Cheng-Yu Long, Feng-Hsiang Tang
Summary: Our data showed that cisplatin treatment induces production of reactive oxygen species (ROS) that regulate apoptotic protein expression and stimulate anti-oxidative signal, inhibiting cell migration. The intervention of Zfp90 enhanced apoptosis pathway and inhibited migrative pathway, thus regulating the sensitivity of ovarian cancer cells to cisplatin. This study suggests that loss of Zfp90 function promotes cisplatin sensitization in ovarian cancer cells through the regulation of Nrf2/HO-1 pathway, enhancing cell apoptosis and inhibiting migration.
Article
Biochemistry & Molecular Biology
Luise Fuhr, Alireza Basti, Teresa Silva Bras, Maria F. Duarte, Angela Relogio
Summary: This study investigated the treatment effect of C. cardunculus on human colorectal cancer cells and found that it directly affects the circadian rhythm of the cells, inhibiting proliferation and inducing cytotoxicity and apoptosis. These findings suggest that C. cardunculus may have a potential role as a modulator of the circadian clock.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Nada Abdullah, Yahya Tamimi, Sergey Dobretsov, Najwa Al Balushi, Jalila Alshekaili, Hamed Al Balushi, Mahmood Al Kindi, Syed Imran Hassan, Shadia Al Bahlani, Benjamin K. Tsang, Ikram A. Burney
Summary: The marine-derived compound MalforminA1 exhibited cytotoxic activity on both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, with a synergistic effect observed when combined with cisplatin. This demonstrates promising potential for MalforminA1 in overcoming drug resistance in ovarian cancer cells. Additionally, down-regulation of bcl2 and p53 genes suggests that MalforminA1 may induce cell death through a non-canonical pathway.
Article
Biochemistry & Molecular Biology
Jianli Yu, Yang Guo, Yi Gu, Fei Li, Haipeng Song, Rui Nian, Xiying Fan, Wenshuai Liu
Summary: In this study, we found that the secretory form of HE4 plays a pro-survival autocrine role in epithelial ovarian cancer (EOC) cells, and the anti-HE4 nanobody can be used as a targeted therapy strategy to improve the therapeutic effects of cisplatin-based chemotherapy.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Review
Pharmacology & Pharmacy
Andrea M. P. Romani
Summary: Cisplatin is a commonly used chemotherapy agent that inhibits the growth of cancer cells by interfering with their DNA repair mechanism. However, its usage is limited due to significant side effects. Recent research has focused on combining cisplatin with other anti-cancer drugs and exploring its immunomodulatory effects.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zhongchao Zhao, Andrea Simms, Nicole F. Steinmetz
Summary: This study utilizes tobacco mosaic virus (TMV) protein nanotubes as drug carriers to deliver platinum therapies to ovarian tumors, increasing efficacy and maintaining safety. It demonstrates superior efficacy compared to free drugs in mouse models and may induce immune response against tumors.
Article
Chemistry, Medicinal
Mengdi Song, Mingxiao Cui, Kehai Liu
Summary: This review discusses the chemotherapeutic drugs and phytochemicals developed to overcome cisplatin-resistance ovarian cancer (CROC), highlighting the significance of combination therapy and the use of a nanoparticle delivery system in reversing cisplatin resistance.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Linjuan Huang, Jing Zhang, Youling Deng, Hao Wang, Piao Zhao, Guozhi Zhao, Wei Zeng, Yonghui Wang, Connie Chen, William Wagstaff, Rex C. Haydon, Russell R. Reid, Tong-Chuan He, Le Shen, Hue H. Luu, Ling Zhao
Summary: Ovarian cancer is a highly lethal malignancy, often diagnosed at advanced stages due to the lack of early diagnosis methods. The standard treatment includes surgery and chemotherapy, but many patients develop chemoresistant tumors. Therefore, there is a need to develop new therapeutic agents to overcome chemoresistance. Niclosamide, an anti-parasite agent, has shown potent anti-cancer activities in ovarian cancer and other types of human cancers. This study investigates the potential of repurposing niclosamide as a therapeutic agent.
Article
Biochemistry & Molecular Biology
Jaemoo Chun
Summary: Isoalantolactone, a compound derived from Inula helenium L., has been identified as a potential glycolysis inhibitor to overcome cisplatin resistance in ovarian cancer. It effectively targets key glycolytic enzymes and enhances sensitivity to cisplatin-induced apoptosis. In vivo studies demonstrate its ability to suppress tumor growth in cisplatin-resistant ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Nicholas Brian Shannon, Laura Ling Ying Tan, Qiu Xuan Tan, Joey Wee-Shan Tan, Josephine Hendrikson, Wai Har Ng, Gillian Ng, Ying Liu, Xing-Yi Sarah Ong, Ravichandran Nadarajah, Jolene Si Min Wong, Grace Hwei Ching Tan, Khee Chee Soo, Melissa Ching Ching Teo, Claramae Shulyn Chia, Chin-Ann Johnny Ong
Summary: This study aimed to identify molecular markers for predicting platinum sensitivity in ovarian cancer patients. Four potential biomarkers were found to have comparable prognostication as clinical information for two-year survival and chemosensitivity prediction. Assessment of tumor biology through gene expression may provide additional information for therapeutic decision making.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Jing Zhao, Wenxi Tan, Lingyi Zhang, Jian Liu, Mengyuan Shangguan, Junyu Chen, Benzheng Zhao, Yuanqing Peng, Manhua Cui, Shuhua Zhao
Summary: This study identified that FGFR3 overexpression enhances DDP-resistance in ovarian cancer by promoting EGFR phosphorylation and activating the PI3K/AKT pathway. FGFR3 was found to be co-expressed with EGFR, and silencing FGFR3 inhibited the activation of the PI3K/AKT pathway and hindered drug resistance and tumor cell development. Targeting FGFR3 and inhibiting EGFR phosphorylation were observed to promote the therapeutic effect of DDP in nude mice.
BIOCHEMICAL PHARMACOLOGY
(2021)